Latest news for Vivesto (OTC:OASMY) Stock

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.

Biotech

News

Health Care

Contracts

General

KZIA

OASMY

Kazia Therapeutics Ltd (NASDAQ: KZIA) has 

Kazia Therapeutics Licenses Cantrixil To Oasmia Pharmaceutical For Ovarian Cancer

Vivesto AB

Nuclear energy stocks and ETFs have come to the fore as ARK Invest&#8217;s founder Cathie Wood <a href="https://www.ark-invest.com/articles/analyst-research/nuclear-energy-could-contribute-meaningfully-to-securing-net-zero-emissions">reshared the firm&#8217;s study </a>on how regulatory hurdles and anti-nuclear sentiment have caused cost overruns and rendered nuclear energy less cost-competitive than natural gas today.
This comes as Tesla Inc. and SpaceX CEO Elon Musk is all set to co-lead the Department of Government Efficiency (DOGE) along with Republican politician Vivek Ramaswamy. As the task force promises to dismantle bureaucracy, reduce regulations, and cut wasteful expenditures, ARKinvest tried to redirect DOGE&#8217;s official page on X (formerly Twitter) to focus on the regulatory hurdles that nuclear energy as a sector has faced in the last 20 years.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Resurfacing this chart amid all the <a href="https://twitter.com/DOGE?ref_src=twsrc%5Etfw">@DOGE</a> talk. U.S. nuclear construction costs declined in accordance with Wright's Law before being derailed by regulatory changes in the 1970s&#8230; Blog and sources: <a href="https://t.co/S2o84BkdA3">https://t.co/S2o84BkdA3</a> <a href="https://t.co/kES3g5Ph80">https://t.co/kES3g5Ph80</a> <a href="https://t.co/VBb6puiP5R">pic.twitter.com/VBb6puiP5R</a>
&mdash; Daniel Maguire (@DMaguireARK) <a href="https://twitter.com/DMaguireARK/status/1857163799037448601?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What Happened: &#8220;The International Energy Agency has identified nuclear energy as vital to achieving net zero emissions by 2050, yet nuclear power in the United States has stagnated at ~20% of the energy mix since the Chernobyl disaster in 1986,&#8221; said an ARKInvest note based on data from IEA as of October 2023.
In addition to its cost-effectiveness, nuclear power provides a reliable, continuous, and carbon-free supply of energy. These are important now since an explosion in demand for artificial intelligence is taxing the electricity consumption of data centers.
Also read: <a href="https://www.benzinga.com/politics/24/11/41962372/trumps-doge-with-musk-at-the-helm-riddled-with-conflicts-of-interest-says-clinton-era-official-robert-reich">Trump&#8217;s DOGE With Musk At The Helm &#8216;Riddled With Conflicts Of Interest&#8217; Says, Clinton-Era Official Robert Reich</a>
Daniel Maguire, research associate at ARKInvest stated in his report dated April 2024 that stringent regulatory changes and anti-nuclear sentiment have stunted the build-out of nuclear capacity and caused cost overruns in developing US nuclear plants.
Regulatory changes in the mid-to-late seventies, including the establishment of the Nuclear Regulatory Commission and the Energy Research and Development Administration, introduced stricter licensing measures, increasing costs significantly. Without such stringent regulations, ARKInvest&#8217;s research suggests that lower cost trajectories could have saved the US about $345 billion, or ~72% of the total.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="754" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014702/Nuclear-plan-costs-1024x754.png" alt="" class="wp-image-652244" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014702/Nuclear-plan-costs-1024x754.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014702/Nuclear-plan-costs-300x221.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014702/Nuclear-plan-costs-768x566.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014702/Nuclear-plan-costs.png 1466w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Why It Matters: With the introduction of the U.S. Advanced Reactor Demonstration Project and other emerging government support programs, nuclear cost overruns should reverse course as countries look for robust clean energy solutions to meet their net carbon emissions reduction commitments.
Maguire&#8217;s tweet shared by Wood, tagged the Department of Government Efficiency, to bring this to light. The department is scheduled to complete its work by July 4, 2026, coinciding with America's 250th independence anniversary. Focus on this area could help spur activity in the nuclear energy sector by developing clean, carbon-free energy production avenues at lower costs.
Also read: <a href="https://www.benzinga.com/government/regulations/24/11/42006530/tesla-ceo-and-doge-co-lead-elon-musk-says-excess-government-spending-causes-inflation-heres-what-experts-say">Tesla CEO And DOGE Co-Lead Elon Musk Says &#8216;Excess Government Spending&#8217; Causes Inflation: Here&#8217;s What Experts Say</a>
Price Action: Despite long-running regulatory hurdles and higher costs, nuclear energy stocks have performed well on a year-to-date basis. Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>), Cameco Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>), Centrus Energy Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>), NuScale Power Corp (SMR) and VanEck Uranium and Nuclear ETF (ACRA: NLR) have all outperformed NYSE composite on a year-to-date basis, which only rose by 16.65%.
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="775" height="289" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014729/stock-list.png" alt="" class="wp-image-652245" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014729/stock-list.png 775w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014729/stock-list-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014729/stock-list-768x286.png 768w" sizes="(max-width: 775px) 100vw, 775px" /></figure>
The five-year charts as per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>, show that Centrus Energy Corp shares have been volatile, whereas NuScale Power Corp has achieved consistent returns.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="271" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks-1024x271.png" alt="" class="wp-image-652246" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks-1024x271.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks-300x79.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks-768x203.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks-1536x406.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/18014753/nuclear-stocks.png 1741w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/markets/24/11/42017638/activist-hedge-fund-valueact-boosts-meta-stake-with-121m-bet-but-ceo-morfit-supports-mark-zuckerberg">Activist Hedge Fund ValueAct Boosts Meta Stake With $121M Bet, But CEO Morfit Supports Mark Zuckerberg&#8217;s AI Vision: Here&#8217;s What Investors Should Know</a>
Image Via Shutterstock

Equities

Markets

OKLO

TLSA

Cathie Wood Redirects Elon Musk's DOGE Focus Toward Nuclear Energy Amid Regulatory Challenges: Here's How Oklo, Cameco, Centrus Energy And Other Stocks Performed

Business Outlook
NIU expects revenues of the fourth quarter 2024 to be in the range of RMB 622 million to RMB 718 million, representing a year-over-year increase of 30% to 50%.

Guidance

Niu Technologies Expects Q4 Revenue Of RMB622M-RMB718M, Up By 30%-50%

The CNN Money Fear and Greed index showed a further decline in the overall market sentiment, with the index moving to the &#8220;Neutral&#8221; zone on Friday.
U.S. stocks settled lower on Friday, with the Dow Jones falling more than 300 points during the session. The S&amp;P 500 recorded a weekly loss of 2.1%, while the Nasdaq Composite fell around 3.2%. The 30-stock Dow lost 1.2% during the week.
Major tech stocks recorded losses, with Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares falling over 3% on Friday, and Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) stock losing around 2.8% during the session. However, shares of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained around 3% on Friday.
Shares of vaccine companies settled lower on Friday after President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS. Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares dipped over 7%, while Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) shares declined more than 4% during the session. The SPDR S&amp;P Biotech ETF dipped over 5%, recording its worst week since 2020.
On the economic data front, U.S. export prices increased by 0.8% in October, while import prices rose by 0.3% month-over-month in October. U.S. retail sales rose 0.4% month-over-month in October compared to a revised 0.8% increase in September, topping market estimates of 0.3%
Most sectors on the S&amp;P 500 closed on a negative note, with information technology, communication services, and healthcare stocks recording the biggest losses on Friday. However, utilities and financials stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 306 points to 43,444.99 on Friday. The S&amp;P 500 fell 1.32% to 5,870.62, while the Nasdaq Composite fell 2.24% at 18,680.12 during Friday's session.
Investors are awaiting earnings results from Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>), and AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 50.9, the index moved to the &#8220;Neutral&#8221; zone on Friday, versus a prior reading of 58.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

AMGN

MRNA

MSFT

NVDA

TCOM

TSLA

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone

Earnings

Niu Technologies Q3 Adj EPADS $(0.06) Up From $(0.14) YoY, Sales $145.90M Vs $127.06M Estimate YoY

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk on Sunday acknowledged the need for bigger, family-sized electric vehicle models from the EV giant.
What Happened: &#8220;Ok,&#8221; Musk wrote to an X user who flagged the need for a bigger Tesla EV for bigger families. 
&#8220;We need big Teslas for big families,&#8221; the user wrote. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Ok
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1858341322496626750?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Tesla unveiled its dedicated <a href="https://www.benzinga.com/news/24/10/41284847/tesla-reveals-two-seater-cybercab-that-drives-itself">robotaxi offering called Cybercab</a> in October, featuring just two seats. Other Tesla vehicles come with five-seat interiors in the U.S., except the long-range all-wheel drive variant of Model Y in which Tesla offers a 7-seat interior option for an added $1,000 or $2,000, depending on the choice of color for the interiors.
Tesla also revealed a Robovan together with the two-seat Cybercab in October with no pedals or wheels capable of transporting up to 20 people or cargo without a driver. However, the company did not provide a production timeline for the vehicle. 
Why It Matters: Musk believes that a <a href="https://www.benzinga.com/news/24/06/39443823/elon-musk-once-said-collapsing-birth-rate-is-the-biggest-danger-civilization-faces-he-has-fathered-1">population collapse</a> is coming with people choosing to have fewer or no children. A population implosion will end civilization, he has previously said, urging people to have more children. 
In September, Reuters reported that Tesla is planning to produce a six-seat version of its&nbsp;<a href="https://www.benzinga.com/news/24/07/39659721/elon-musk-denies-rumors-of-model-y-refresh-yet-again-urges-fans-to-stop-speculating-over-fear-of-hur" target="_blank" rel="noreferrer noopener">Model Y SUV</a>&nbsp;starting next year in China.
The new variant of Tesla's best-selling vehicle will be made at the company's gigafactory in Shanghai starting late 2025, <a href="https://www.benzinga.com/news/24/09/40679900/tesla-plans-6-seat-model-y-production-in-china-starting-in-2025-report">Reuters reported</a>, citing two people familiar with the matter.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42025066/elon-musks-spacex-delays-starship-test-flight-next-attempt-now-set-for-tuesday" target="_blank" rel="noreferrer noopener">Elon Musk's SpaceX Delays Starship Test Flight, Next Attempt Now Set For Tuesday</a></li>
</ul>
Photo courtesy: Tesla

Tech

Elon Musk Acknowledges X User's Call for Larger Tesla Models For Bigger Families

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Brady Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRC#NYSE">BRC</a>) to report quarterly earnings at $1.10 per share on revenue of $365.88 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Brady shares rose 0.2% to $74.38 in after-hours trading.</li>
<li>Analysts expect AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) to post quarterly earnings at $1.24 per share on revenue of $4.14 billion. The company will release earnings after the markets close. AECOM shares gained 0.1% to $106.99 in after-hours trading.</li>
<li>IT Tech Packaging (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) reported a loss of 20 cents per share for the third quarter, unchanged from the year-ago period. The company's sales jumped around 59% year-over-year to $25.08 million. IT Tech Packaging shares fell 0.6% to $0.2495 in the after-hours trading session.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Before the markets open, Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) is projected to report a quarterly loss at 10 cents per share on revenue of $78.85 million. Bitdeer Technologies shares gained 1.1% to $11.21 in after-hours trading.</li>
<li>Analysts expect Trip.com Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>) to report quarterly earnings at 91 cents per share on revenue of $2.20 billion after the closing bell. Trip.com Group shares slipped 0.01% to $59.48 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42024062/how-to-earn-500-a-month-from-apple-stock">How To Earn $500 A Month From Apple Stock</a></li>
</ul>
Photo courtesy: Shutterstock

BTDR

Brady, Aecom And 3 Stocks To Watch Heading Into Monday

Global investment banks revealed significant positions held in cryptocurrency-related exchange-traded funds (ETFs) and Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) stock MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), according to their latest 13F filings with the SEC.
JPMorgan Chase
JPMorgan Chase &amp; Co., the world&#8217;s largest bank by market capitalization, made sizable investments in Bitcoin and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) ETFs for the quarter ending Sept. 30.
The bank purchased 387 shares, worth $13,982, of iShares Bitcoin Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>) after offloading them all in the last quarter.
JPMorgan also reallocated to Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>), bagging 213 shares worth $11,877. Overall, the banking giant's Bitcoin ETF exposure reached nearly $65,000.
JPMorgan tapped into the Ethereum ETFs for the first time, with sizable investments in Grayscale Ethereum Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETHE#NYSE">ETHE</a>) and its miniature version, Grayscale Ethereum Mini Trust ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETH#NYSE">ETH</a>). Together, its stake in the two funds amounted to roughly $30,700.
The bid to increase cryptocurrency exposure caused JPMorgan to boost its MicroStrategy portfolio by 12.5% to 660,693 at the end of Q3, worth $111.39 million.&nbsp;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41873427/shiba-inu-lead-developer-shytoshi-kusama-pitches-s-h-i-b-in-response-to-elon-musks-call-for-new-roles-recommendations-in-trump-administration">Shiba Inu Lead Developer Shytoshi Kusama Pitches S.H.I.B In Response To Elon Musk&#8217;s Call For New Roles Recommendations In Trump Administration</a>
Goldman Sachs
Another Wall Street giant, Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), reported its 13F filing last week.
The bank <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42010782/goldman-sachs-expands-bitcoin-etf-holdings-to-710-million">disclosed </a>$710 million invested across multiple Bitcoin ETFs, with a stake of 12.7 million shares valued at $461 million in IBIT.&nbsp;
These investments solidified Goldman&#8217;s position as the second-largest holder of IBIT, now the world's biggest Bitcoin investment fund, with assets worth $42.89 billion as of this writing.&nbsp;
Goldman Sachs holds $25.16 million in Ethereum ETFs, split between Grayscale&#8217;s Mini Trust and Fidelity&#8217;s Ethereum Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FETH#BATS">FETH</a>).
Interestingly, the banking juggernaut liquidated around 534,894 shares of MicroStrategy in Q3, reducing its stake to $140.44 million.
Morgan Stanley
Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) downsized its Bitcoin ETF portfolio to $183.39 million, from $203 million in the <a href="https://www.benzinga.com/markets/cryptocurrency/24/08/40410418/goldman-sachs-makes-blockbuster-debut-adds-over-400m-in-bitcoin-etf-position-in-q2-as-morg">last quarter.</a> 
The outflows were primarily driven by the selling of 449,802 IBIT shares.
Additionally, Morgan Stanley invested in Ethereum ETFs, primarily through a stake in iShares Ethereum Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETHA#NASDAQ">ETHA</a>).
Meanwhile, its MicroStrategy position jumped 22.6% to 9,595,008 shares worth $1.61 billion. 
Photo by Avi Rozen on Shutterstock
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42027183/michael-saylor-predicts-bitcoin-boom-says-100k-on-the-horizon">Michael Saylor Predicts Bitcoin Boom, Says $100K On The Horizon</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

ETHA

ETHE

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

IBIT

MSTR

Wall Street's Banking Giants Load Up On Bitcoin, Ethereum ETFs: Here's What JPMorgan, Goldman Sachs And Morgan Stanley Hold

PROC

Reported Friday, Procaps Faces Nasdaq Delisting Threat Due To Form 20-F Filing Delay, Seeks Hearing And Stay To Avoid Suspension

A prominent Wall Street analyst has reported a milestone for Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Full Self-Driving technology, completing an unassisted journey from Manhattan to Connecticut, marking a notable advancement in the <a href="https://www.benzinga.com/news/global/24/11/42028323/gary-black-defends-tesla-strategy-amid-clash-with-elon-musk-bulls-we-dont-trade-tesla-we-trim-when-the-price-goes-higher">company&#8217;s autonomous driving capabilities</a>.
What Happened: Pierre Ferragu, an analyst at New Street Research, shared his experience on X, formerly Twitter, stating, &#8220;Last night FSD got me out of deep into Manhattan and drove me back home to Connecticut. Got through a number of challenging and confusing situations with mastery. Not a single intervention. Robotaxi never felt that close ever before.&#8221;
For context, the drive from Manhattan to Connecticut spans approximately 94.7 miles and typically takes up to 1 hour and 45 minutes.
The successful navigation of complex urban environments represents a significant step forward for Tesla&#8217;s autonomous driving technology, particularly in challenging city conditions where s<a href="https://www.benzinga.com/news/24/09/41047267/safety-disaster-tesla-fsd-galaxies-away-from-being-anywhere-close-to-competition-says-bearish-analys">elf-driving systems typically face their greatest tests</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Last night FSD got me out of deep into Manhattan and drove me back home to Connecticut. Got through a number of challenging and confusing situation with mastery. Not a single intervention. Robotaxi never felt that close ever before…
&mdash; Pierre Ferragu (@p_ferragu) <a href="https://twitter.com/p_ferragu/status/1858138037009424474?ref_src=twsrc%5Etfw">November 17, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
This development comes as Tesla continues to enhance its FSD technology amid growing competition in the autonomous vehicle sector from companies like Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)-backed Waymo, Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>). 
See Also: <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">Nvidia&#8217;s Blackwell Chips Are Extra Toasty, Server Overheating Issues Impact Meta, Microsoft And Elon Musk&#8217;s xAI</a>
Why It Matters: The achievement is particularly notable given New York City&#8217;s demanding driving environment, known for its dense traffic, complex intersections, and unpredictable pedestrian movements.
Tesla&#8217;s autonomous driving progress comes at a crucial time as reports suggest a potential easing of federal regulations for self-driving vehicles, which could <a href="https://www.benzinga.com/markets/equities/24/11/42028797/tesla-soars-over-5-in-overnight-trading-as-trump-administration-reportedly-seeks-to-ease-fsd-norms">accelerate the company&#8217;s robotaxi ambitions</a>.
The stock has shown significant volatility over the past year, trading between $138.80 and $358.64, as investors weigh the company&#8217;s autonomous driving progress against market challenges, including changes to the federal EV tax credit structure.
Price Action: Tesla stock closed at $320.72 on Friday, gaining 3.07% for the day. In after-hours trading, the stock edged up 0.0062%. Year to date, Tesla's stock has risen by 29.10%, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42028523/cathie-wood-draws-reagan-era-parallels-as-elon-musk-takes-doge-helm-this-bull-market-has-just-begun-to-broaden-out">Cathie Wood Draws Reagan-Era Parallels As Elon Musk Takes DOGE Helm: &#8216;This Bull Market Has Just Begun To Broaden Out&#8217;</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BIDU

GOOG

GOOGL

MBLY

Pierre Ferragu Says 'Robotaxi Never Felt That Close Ever Before' After Tesla Drove Through Challenging Roads With No Intervention

Elon Musk has predicted that AI will surpass doctors and lawyers after a study revealed OpenAI&#8217;s ChatGPT-4 outperformed medical professionals in diagnosing illnesses.
What Happened: A study <a href="https://www.nytimes.com/2024/11/17/health/chatgpt-ai-doctors-diagnosis.html">reported</a> by&nbsp;The New York Times&nbsp;revealed that AI achieved a 90% accuracy rate, compared to 76% for doctors using ChatGPT as a tool and 74% for doctors relying on traditional resources.
Following the publication of the report, Bindu Reddy, CEO of Abacus.AI, stated that an AI doctor with access to all lab reports would be able to diagnose problems and&nbsp;suggest remedies better than most&nbsp;human doctors.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/41932289/ai-capabilities-plateauing-say-andreessen-horowitz-founders-echoing-concerns-of-openai-co-founder-ilya-sutskever?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AI Capabilities Plateauing, Say Andreessen Horowitz Founders, Echoing Concerns Of OpenAI Co-Founder Ilya Sutskever</a>
She added that the same would be true for lawyers and other knowledge-heavy professions.
Musk agreed with Reddy&#8217;s prediction, stating,&nbsp;&#8220;We can&nbsp;serve as a biological backstop&nbsp;for intelligence, as we are&nbsp;less brittle than silicon, and&nbsp;perhaps as a source of&nbsp;will.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">AI will soon beat doctors and lawyers by a large margin (and eventually all humans at almost everything). We can serve as a biological backstop for intelligence, as we are less brittle than silicon, and perhaps as a source of will.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1858305249783755206?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: Last month, while speaking with Dr. Peter H. Diamandis, founder and executive chairman of the&nbsp;XPRIZE Foundation, Musk predicted that AI could <a href="https://www.benzinga.com/news/24/10/41618261/elon-musk-predicts-ai-will-match-human-capabilities-in-few-years-the-cup-is-80-full-maybe-90">reach human-level capabilities by 2029</a>.
Previously, the tech mogul has also said&nbsp;that the <a href="https://www.benzinga.com/news/24/06/39246781/elon-musk-thinks-humanoid-robots-will-one-day-exceed-human-population-from-nvidias-project-gr00t-to">number of humanoid robots</a> will one day exceed the human population.
&#8220;I think, long-term… the ratio of humanoid robots will be more than one-to-one. So, there probably might be two humanoid robots, or more, maybe 10, for every one human,&#8221; he earlier this year.
Earlier, Roman Yampolskiy, an AI safety researcher, also said that Musk&#8217;s company Neuralink, which aims to merge <a href="https://www.benzinga.com/news/24/06/39138007/elon-musks-neuralink-incredible-technology-can-make-humans-superhuman-says-ai-expert-but-warns-of-fu">human brains with Artificial General Intelligence</a> (AGI), could potentially make humans obsolete.
Image via Shutterstock
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/retail-sales/24/11/42024288/consumer-tech-news-november-11-15-apple-plans-to-launch-an-ai-wall-tablet-meta-plans-to-introduce-ads-on-threads-more?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Consumer Tech News (November 11-15): Apple Plans To Launch An AI Wall Tablet, Meta Plans To Introduce Ads On Threads &amp; More</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Elon Musk Says AI Will Surpass Doctors, Lawyers After ChatGPT Tops Medical Diagnoses — Humans Becoming 'Biological' Backups

Dell Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) has reached a major milestone by becoming the first company to deliver a new generation of super-powerful computer systems designed specifically for artificial intelligence.
What Happened: Michael Dell, the company&#8217;s CEO, announced on social media platform X that Dell is shipping its first liquid-cooled PowerEdge XE9712 systems to CoreWeave, a company that provides computing power for AI applications.
&#8220;The AI rocket just got a massive boost!&#8221; Michael Dell in his announcement, highlighted the significance of this achievement.
These new systems, developed in partnership with tech giant NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), are unlike traditional computers. They use special cooling technology that helps them handle the intense processing needed for advanced AI tasks. Think of it as the difference between a regular car engine and a Formula 1 racing engine – both are engines, but one is designed for much more powerful performance.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The 1st in the world <a href="https://twitter.com/nvidia?ref_src=twsrc%5Etfw">@nvidia</a> GB200 NVL72 server racks are now shipping. We are thrilled to deliver our liquid-cooled PowerEdge XE9712 to <a href="https://twitter.com/CoreWeave?ref_src=twsrc%5Etfw">@CoreWeave</a>. The AI rocket just got a massive boost! &#x1f916;&#x1f680;&#x1f91d; <a href="https://t.co/2QzlxbQE5f">pic.twitter.com/2QzlxbQE5f</a>
&mdash; Michael Dell (@MichaelDell) <a href="https://twitter.com/MichaelDell/status/1858306164775379268?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake">Peter Thiel Says Trump&#8217;s 60% China Tariff Would Be &#8216;Very, Very Bad&#8217; For Beijing, Here&#8217;s What&#8217;s At Stake</a>
Why It Matters: The system, called the GB200 NVL72, combines 72 powerful processing chips (GPUs) and 36 central computers (CPUs) working together as one unit. This allows it to run AI programs 30 times faster than previous systems, particularly when handling complex AI tasks like chatbots and image generation.
CoreWeave, the company receiving these first systems, specializes in providing high-powered computing services to businesses working with AI. They work closely with Nvidia, which designed the core technology inside these systems.
This development is particularly important as companies worldwide are racing to build and access more powerful AI computing systems. Industry experts predict high demand for these systems, with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39168191/nvidia-maintains-lead-as-key-ai-beneficiary-analyst-boosts-estimates-after-taiwan-e">estimates suggesting 20,000 to 25,000 similar systems could be shipped in 2025</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42028523/cathie-wood-draws-reagan-era-parallels-as-elon-musk-takes-doge-helm-this-bull-market-has-just-begun-to-broaden-out">Cathie Wood Draws Reagan-Era Parallels As Elon Musk Takes DOGE Helm: &#8216;This Bull Market Has Just Begun To Broaden Out&#8217;</a></li>
</ul>
Image Via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

DELL

Dell Ships First 72-Nvidia GPU Monster: 'AI Rocket Just Got A Massive Boost,' Says CEO

<ul>
<li>Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life</li>
<li>New Data from FOREST-HCM Demonstrate Aficamten Durably Reduces the Proportion of Patients Guideline Eligible for Septal Reduction Therapy</li>
<li>Analyses of Real-World Data Reveal Cost of Care Differences in HCM&nbsp;Across Gender, Age and Race/Ethnicity</li>
</ul>

CYTK

Reported Saturday, Cytokinetics Unveils New Data On Aficamten And Hypertrophic Cardiomyopathy At AHA Scientific Sessions 2024

Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
"These analyses reinforce the potential treatment benefit of omecamtiv mecarbil in patients from GALACTIC-HF who are at higher risk, such as older patients or those with a recent ventricular arrhythmia," said Stuart Kupfer, M.D., Senior Vice President, Chief Medical Officer. "As we prepare for the start of COMET-HF, the confirmatory Phase 3 clinical trial of omecamtiv mecarbil, we look forward to evaluating its potential to reduce the risk of adverse heart failure outcomes across the spectrum of these very high-risk patients failing guideline-directed medical therapy."

Reported Saturday, Cytokinetics Shares Additional GALACTIC-HF Insights At AHA 2024

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

ACET

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

<ul>
<li>In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations</li>
<li>Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation</li>
<li>Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies</li>
</ul>

Reported Saturday, Eli Lilly's Tirzepatide Cuts Heart Failure Risk By 38% In Adults With Heart Failure With Preserved Ejection Fraction (HFpEF) And Obesity

On Sunday, President-elect Donald Trump picked pro-Starlink Republican Brendan Carr as chairman of the Federal Communications Commission, or FCC.
What Happened: &#8220;Commissioner Carr is a warrior for Free Speech, and has fought against the regulatory Lawfare that has stifled Americans&#8217; Freedoms, and held back our Economy. He will end the regulatory onslaught that has been crippling America&#8217;s Job Creators and Innovators, and ensure that the FCC delivers for rural America,&#8221; Trump wrote in his statement. 
Carr, a vocal critic of big tech companies, wrote on X that he is &#8220;humbled and noted&#8221; to take on the role. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you, President Trump! I am humbled and honored to serve as Chairman of the FCC. Now we get to work. &#x1f1fa;&#x1f1f8; <a href="https://t.co/MPyL2d38kT">pic.twitter.com/MPyL2d38kT</a>
&mdash; Brendan Carr (@BrendanCarrFCC) <a href="https://twitter.com/BrendanCarrFCC/status/1858311955024400868?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Carr wrote last week that &#8220;Facebook, Google, Apple, Microsoft, and others have played central roles in the censorship cartel,&#8221; adding that they must be &#8220;dismantled.&#8221;
Carr currently serves as the senior Republican on the FCC. The FCC is an independent U.S. government agency overseen by Congress and regulates interstate and international communications by radio, television, wire, satellite, and cable in all 50 states, the District of Columbia, and U.S. territories. 
Jessica Rosenworcel currently serves as the Chairperson of the Commission. 
Why It Matters: Carr is a strong supporter of Musk&#8217;s Starlink. He staunchly <a href="https://www.benzinga.com/news/24/09/40672229/starlink-ineligible-for-nearly-900m-in-subsidies-says-fcc-spacex-ceo-elon-musk-says-it-is-flat-out-l">opposed the FCC&#8217;s decision not to offer nearly $900 million in subsidies to Starlink</a> alleging that the FCC had added itself to the growing list of administrative agencies taking action against Musk's businesses following the billionaire's acquisition of Twitter (now X) on the instructions of President Joe Biden. 
Carr also said on Monday that the FCC will stop promoting Diversity, Equity, Inclusion, and Accessibility (DEI) initiatives.
&#8220;The FCC's most recent budget request said that promoting DEI was the agency's second-highest strategic goal. Starting next year, the FCC will end its promotion of DEI,&#8221; he wrote on X. 
Musk is also staunchly <a href="https://www.benzinga.com/news/24/04/38064076/mark-cuban-vows-to-defend-deis-positive-impact-on-business-because-they-are-opposite-of-elon-musk-an">opposed to DEI programs</a>, terming them &#8220;racist.&#8221; Musk regards preference for certain sections of the population in DEI programs as &#8220;racism&#8221; towards the majority white population. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42025362/former-uber-executive-and-3-congressmen-contenders-for-trumps-transportation-chief-role-report">Former Uber Executive And 3 Congressmen Contenders For Trump&#8217;s Transportation Chief Role: Report</a></li>
</ul>
Photo courtesy: Gage Skidmore via Flickr

SPACE

Trump Names Pro-Starlink FCC Commissioner Brendan Carr As Chairperson, Says He Will 'End The Regulatory Onslaught'

<ul>
<li>Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis</li>
<li>Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients</li>
<li>Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline</li>
<li>Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients</li>
<li>Favorable safety and tolerability profile observed</li>
<li>ATTR-CM data presented at the 2024 AHA Scientific Sessions and published in the New England Journal of Medicine</li>
</ul>

NTLA

Reported Saturday, Intellia Announced Initial Phase 1 Data Suggesting Nexiguran Ziclumeran, An In Vivo CRISPR/Cas9 Gene Editing Therapy, May Benefit ATTR Amyloidosis Progression

BMRN

Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024

BioCryst Pharmaceuticals, Inc.&nbsp;(Nasdaq:&nbsp;BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO&#xAE;&nbsp;(berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
"The positive HSE recommendation of ORLADEYO&nbsp;broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland," said Charlie Gayer, chief commercial officer of BioCryst.
The HSE decision in Ireland follows the European Commission marketing authorization of ORLADEYO in April 2021. To date, ORLADEYO is licensed in 44 countries.

Government

Regulations

BCRX

BioCryst's ORLADEYO Gets Ireland's Approval: Expanding Access to Once-Daily HAE Therapy

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation

Reported Saturday, Boston Scientific's WATCHMAN FLX Device Shows Superior Bleeding Risk Reduction Compared To Oral Anticoagulants After Cardiac Ablation In OPTION Clinical Trial

Vivesto

Kazia Therapeutics Ltd&nbsp;(NASDAQ:&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/stock/kzia#NASDAQ" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">KZIA</a>) has&nbsp;<a class="editor-rtfLink" href="https://www.prnewswire.co.uk/news-releases/kazia-licenses-cantrixil-a-clinical-stage-first-in-class-ovarian-cancer-drug-candidate-to-oasmia-pharmacetical-ab-885769945.html" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">entered an exclusive worldwide licensing</a>&nbsp;agreement with&nbsp;Oasmia Pharmaceutical AB&nbsp;(OTC:<a class="ticker" href="/stock/OASMY#OTC">OASMY</a>) for Cantrixil under development the treatment of ovarian cancer.

<ul>
	<li>The agreement will see Sweden-based Oasmia assume exclusive worldwide rights to develop and commercialize Cantrixil for all indications, with an initial focus on ovarian cancer.</li>
	<li>Oasmia&#39;s lead product, Apealea (paclitaxel micellar), is approved in Europe for adult patients with the first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, and is in late-stage development in the U.S.</li>
	<li>Oasmia expects to commence a Phase 2 study of Cantrixil in ovarian cancer in 2022.</li>
	<li>Under the terms of the agreement, Oasmia will make an upfront payment of $4 million to Kazia, with contingent milestone payments of up to $42 million and double-digit royalties on commercial sales.</li>
	<li>Cantrixil is a proprietary formulation of the potent and selective third-generation benzopyran, TRX-E-002-1, that targets the entire spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) thought to be responsible for disease relapse.</li>
	<li>In December last year, Kazia&nbsp;<a class="editor-rtfLink" href="https://www.benzinga.com/pressreleases/20/12/n18715681/top-line-final-data-from-cantrixil-phase-i-study-confirms-prior-positive-efficacy-and-safety-signa" style="color: rgb(14, 16, 26); background: transparent; margin-top:0pt; margin-bottom:0pt;; color: #4a6ee0;" target="_blank">announced&nbsp;</a>a Phase 1 study&#39;s top-line results and determined the maximum tolerated dose of Cantrixil to be 5 mg/kg.</li>
	<li>Price Action:&nbsp;KZIA closed 3.9% lower at 9.9 on Friday.</li>
</ul>

Comments

Vivesto

News

Latest news for Vivesto (OTC:OASMY) Stock

Monday, March 01, 2021

Friday, December 06, 2019

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga